NLNK - NewLink Genetics Corporation
| Previous Close | 1.6900 |
| Open | 1.6900 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 39400 |
| Day's Range | 1.6900 - 1.8300 |
| 52 Week Range | 1.2800 - 5.6100 |
| Volume | 741,204 |
| Avg. Volume | 512,462 |
| Market Cap | 67.47M |
| Beta (3Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2180 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of NLNK earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 NewLink Genetics Corp Earnings Call
- Associated Press•14 days ago
NewLink: 1Q Earnings Snapshot
On a per-share basis, the Ames, Iowa-based company said it had a loss of 27 cents. The biopharmaceutical company posted revenue of $106,000 in the period. In the final minutes of trading on Wednesday, ...
- GlobeNewswire•14 days ago
NewLink Genetics Reports First Quarter 2019 Financial Results and Provides Clinical Activities Update
AMES, Iowa, May 08, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the first quarter ended March 31, 2019 and provided an update on.
- GlobeNewswire•17 days ago
NewLink Genetics to Participate in Upcoming Investor and Medical Conferences
AMES, Iowa, May 06, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences:.
- Simply Wall St.•27 days ago
NewLink Genetics Corporation (NASDAQ:NLNK): Earnings Expected To Remain Subdued
NewLink Genetics Corporation's (NASDAQ:NLNK) released its most recent earnings update in December 2018, which indicated that losses became smaller relative to the prior year's level - great news for...
- GlobeNewswire•29 days ago
NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019
NewLink Genetics Corporation (NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial results and provide an update of its clinical development activities. Investors and the general public are invited to listen to a live audio webcast of the conference call, which can be accessed five minutes prior to the start of the call by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international). The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/df4rgjiz.
- GlobeNewswire•2 months ago
NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
AMES, Iowa, April 02, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase.
- Zacks•2 months ago
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
- Zacks•2 months ago
4 Small Biotech Stocks Likely to Witness More Upside in 2019
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NLNK earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 NewLink Genetics Corp Earnings Call
- Simply Wall St.•3 months ago
Do Institutions Own Shares In NewLink Genetics Corporation (NASDAQ:NLNK)?
The big shareholder groups in NewLink Genetics Corporation (NASDAQ:NLNK) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders ownRead More...
- GlobeNewswire•3 months ago
NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
AMES, Iowa, Feb. 27, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207, a.
- GlobeNewswire•3 months ago
NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
AMES, Iowa, Feb. 27, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and year ended 2018, as well as.
- GlobeNewswire•3 months ago
NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
NewLink Genetics Corporation (NLNK) today announced that it will release its fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019. NewLink Genetics' senior management team will host the conference call, which will be open to all listeners. The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/dqg32drc.
- GlobeNewswire•4 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within Marathon Oil, Accuray, United Natural Foods, Systemax, Amgen, and NewLink Genetics — New Research Emphasizes Economic Growth
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
NewLink Genetics to Participate in the Immuno-Oncology 360° Conference
Dr. Link’s presentation, “IDO Changes the T-cell Balance in the Tumor Microenvironment,” will occur on Wednesday, February 6th, at 9:15 AM ET, and will include a discussion of immune regulation in the tumor microenvironment and how indoximod’s mechanism of action lends itself to counter multiple elements of immune regulation. NewLink Genetics is a clinical stage biopharmaceutical company focused on developing novel immuno-oncology product candidates to improve the lives of patients with cancer.
- Simply Wall St.•4 months ago
Before You Buy NewLink Genetics Corporation (NASDAQ:NLNK), Consider Its Volatility
If you're interested in NewLink Genetics Corporation (NASDAQ:NLNK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
- Business Wire•6 months ago
NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
AMES, Iowa & SAN DIEGO-- -- Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease negativity rate of 86% and post-consolidation MRD negativity of 100% Safety data from this study indicate the combination treatment regimen was well tolerated with no regimen limiting toxicities observed NewLink Genetics Corporation announced ...
- Simply Wall St.•6 months ago
Does NewLink Genetics Corporation’s (NASDAQ:NLNK) CEO Salary Compare Well With Others?
Charles Link has been the CEO of NewLink Genetics Corporation (NASDAQ:NLNK) since 2003. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of NLNK earnings conference call or presentation 1-Nov-18 8:30pm GMT
Q3 2018 NewLink Genetics Corp Earnings Call
- GlobeNewswire•6 months ago
NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
NewLink Genetics Corporation (NLNK) reported today that Merck has begun the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated). This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by Merck in July 2016 and is anticipated to be completed in 2019.
- GlobeNewswire•6 months ago
NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumor Microenvironment at SITC 2018
AMES, Iowa, Nov. 09, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that data from three separate trials are being presented at the Society for Immunotherapy of.
- GlobeNewswire•7 months ago
NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
AMES, Iowa, Nov. 06, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the following abstracts have been published and are now available on the Society.
- GlobeNewswire•7 months ago
Analysis: Positioning to Benefit within Mercury, Lincoln Electric, Sprint, Fred's, NewLink Genetics, and El Paso Electric — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•7 months ago
Is the Options Market Predicting a Spike in NewLink Genetics (NLNK) Stock? (revised)
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
